Alvotech Reveals Action Date For Interchangeable Adalimumab BLA
FDA Has Accepted AVT02 BLA For Review Including New Data
While awaiting news from the FDA for its biosimilar application referencing the higher-concentration formulation of Humira, Alvotech has announced that the FDA has accepted its BLA supporting interchangeability for the AVT02 candidate.
